Skip to content
Biodatica
Start free

Princess Maxima Center for Pediatric Oncology

Vienna, Utrecht

OncologyCAR-TPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: International Leukemia Target Board

6mo agoTrial registeredJan 9, 2026Source filing (opens the source filing in a new tab)

Momentum

89no change

Momentum 89 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

567 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Oct 1, 2025

    Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

    ClinicalTrials.gov · NCT05745714 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Oct 1, 2025

    Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

    ClinicalTrials.gov · NCT05751044 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Feb 6, 2024

    Acute Myeloid Leukemia in Children · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

    ClinicalTrials.gov · NCT06262438 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Nov 14, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

    ClinicalTrials.gov · NCT05658640 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Jul 14, 2023

    Acute Myeloid Leukemia in Children · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

    ClinicalTrials.gov · NCT05994690 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Dec 31, 2022

    Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · International Leukemia Target Board

    ClinicalTrials.gov · NCT05270096 (opens the source filing in a new tab)

  7. Trial

    PHASE1/PHASE2 registered

    Aug 18, 2022

    Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor · RECRUITING · sponsor: Princess Maxima Center for Pediatric Oncology · Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

    ClinicalTrials.gov · NCT04925609 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources